Skip to main content

01.12.2018 | Study protocol | Ausgabe 1/2018 Open Access

BMC Cancer 1/2018

Staging laparoscopy for locally advanced gastric cancer in Chinese patients: a multicenter prospective registry study

BMC Cancer > Ausgabe 1/2018
Ziyu Li, Zhemin Li, Lianhai Zhang, Qian Liu, Zhenjun Wang, Zhongtao Zhang, Gang Xiao, Wei Fu, Xin Wang, Yingjiang Ye, Jianchun Yu, Fei Li, Lin Chen, Shibin Wang, Jiafu Ji
Area under curve
Computed Tomography
Endoscopic ultrasonography
Objective performance criteria
Receiver-operator characteristic
Staging laparoscopy


Gastric cancer is a major cause of cancer death worldwide with a 40 percentage of cases occurring in China [ 1]. Individualized treatment based upon tumor stage takes on a widely accepted strategy, and surgery remains the most effective treatment modality.
Most of the Chinese patients are diagnosed with locally advanced stage, suffering the substantial intra-abdominal metastases with higher risks. Precise preoperative staging is particularly important for therapeutic strategies and prognostic evaluation.
Precise staging is a foremost method that benefits the successful surgical intervention of cancer, contributed to the improvement of medical tools: despite the fact that preoperative imaging techniques have significantly improved the diagnostic accuracy of wall infiltration and lymph node involvement, the detection of peritoneal dissemination still needs to be developed; positive intra-peritoneal findings of free cancer cells has been proved to be related with poor survival yet could only be confirmed during surgical procedure [ 2, 3].
SL has been suggested useful in detecting unrecognized peritoneal dissemination, and in collecting peritoneal lavage fluid for cytological examination with minimal invasion. However, indication for SL remains controversial. NCCN guideline recommends an indication for SL of T3 and/or N+; ESMO, IB-III; JGCA, none, merely mentioned SL only on the condition of neoadjuvant Chemoradiotherapy [ 46]. No specific recommended indications for Chinese patients can be referred to for lack of solid evidence.
The aim of this study is to acquire a basic data on the positive rate of SL in Chinese patients and to identify the risk factors associated with intra-abdominal metastasis.


The design of study

This study evaluates the efficacy of SL with peritoneal cytology, and determine the indications if possible.
Patients who meet the inclusion criteria will be enrolled consecutively, with their preliminary data collected using a web-based case report form. When the whole data-collecting is completed, factors associated with intra-abdominal metastasis will be analyzed by multivariate Cox regression model. Receiver-operator characteristic (ROC) will be used to find out risk factors of intra-abdominal metastasis. Figure 1 shows the CONSORT diagram.


Patients with pathologically confirmed gastric adenocarcinoma are recruited. If the patient meets all inclusion criteria, following data will be recorded: basic information including age, gender, height, body weight et al., clinical information including CT stage(enhanced CT is mandatory required), EUS stage, result of blood examinations such as tumor marker (CEA, CA19-9, CA72-4, CA12-5), blood cell count, albumin et al. If there been any differences between CT & EUS, it is required to record them separately.

Staging laparoscopy

If the patient is confirmed at stage cT2-4bN0-3 M0, which means no sign of distant metastasis detected by CT/EUS, he/she undergoes SL. Following data will be recorded: intraoperative finding including the peritoneal dissemination, and the peritoneal lavage; video of surgery and pictures demonstrating the extent of peritoneal dissemination is required.


Postoperative hospital stay and complications will be recorded, the follow-up time will be 30 days after surgery. Only those who undergoes DL alone will be included into safety analysis since the complications will be confused if the patient undergo radical surgery immediately after SL.

Study endpoint

The primary target of this study is to obtain the result of SL. Either peritoneal dissemination or a positive result of cytological examination will be recorded as a positive result. If the pathological or cytological examination describes “suspicious”, the result will be characterized as positive, consistent with our current practice.
The secondary aim is to evaluate the safety of SL.

Selection of candidate patients

Age ≥ 18;
Histological confirmed diagnosis of primary gastric carcinoma (including esophagus-gastric junction).
Karnofsky score ≥ 70;
Abdominally enhanced spinal CT and endoscopic ultrasonography (EUS) showed a clinical stage of T2-4bN0-3bM0;
Fit for radical gastrectomy or neo-adjuvant chemotherapy;
Willing to comply with protocol, and provide informed consent forum.
The exclusion criteria included:
Unfit for laparoscopic operation or general anesthesia (suspicious abdominal adhesions, severe cardiopulmonary disease, etc.);
Underwent emergency surgery to relieve obstruction, bleeding or perforation.

SL technique

SL was performed under general anesthesia. The patient is placed in a supine position. A 10-mm disposable trocar (observing hole) is inserted into the sub-umbilicus, and a 30° telescope is used. Another 10-mm trocar and a 5-mm trocar (operating hole) are inserted into the right upper quadrant and left upper quadrant, respectively. Prior to any manipulation, 250 ml of warm normal saline is infused into subphrenic space, subhepatic space, omentum, bilateral paracolic sulci and the pouch of Douglas. The irrigation should be carefully operated to avoid the primary tumor. At least 100 ml of fluid is aspirated from the subphrenic space, subhepatic space and Douglas’ pouch. The fluid is immediately sent for centrifugation and cytological examination and a systematic inspection of the abdominal cavity is performed clockwise from the right quadrant. Any suspicious lesion will be biopsied and sent for frozen pathologic examination.

Sample size

This study is a single arm OPC (objective performance criteria) design where the primary evaluation index is the positive rate of SL. Based upon literature, expected event rate is 20%, and clinical acceptable rate is above 15%. Type I error as bilateral 5%, dropout rate as 5%, power as 80%, calculated sample size is 450. The recruitment process is estimated to be completed by December 2016.

Data analysis

Clinical characteristics of the DL- and DL+ patients are compared using the Independent samples group t test and chi-square test. To determine the risk factors, all variables found to be significant by the univariate analysis are assessed by binary logistic regression analysis (Method: Backward: Wald, probability for stepwise: 0.5 for entry, 1.0 for removal). The ROC curve and AUC analyses are used to determine sensitivity, specificity, and corresponding cut-off value of each factor. All P values < .05 are considered statistically significant. All statistical analyses are carried out using the SPSS statistical software package (version 20).


This study is conducted to prospectively evaluate the positive rate of the result of SL based on samples of Chinese patient and try to discover risk factors of intra-abdominal metastasis. SL has been recommended by many guidelines yet different indications is suggested. The standardized operational procedure remains controversial for such practice along with possibly unknown bias. Druing the process of information collecting, data will be prospectively recorded using web-based case report forms.
The results of the study will provide the first prospective multi-center database of SL in China, according to our knowledge, which will provide important figure of 40% of patients of the world.




This work was supported by grants supporting the research program of early diagnosis, standardized treatment and therapy effect evaluation of gastric cancer (D141100000414004) form Beijing Ministry of Science and Technology.

Availability of data and materials

Since this article is study protocol, it’s not applicable.

Authors’ information


Ethics approval and consent to participate

This study is conducted in accordance with the “Declaration of Helsinki” and “Ethical Guidelines for Clinical Research”, and has been approved by the Institutional Review Boards of each participating institute. Written informed consent is obtained from all patients before enrollment.
IRBs list:
Ethic Committee of Beijing Cancer Hospital (Peking University Cancer Hospital & Institute).
Ethic Committee of Cancer Hospital and Institute, Chinese Academy of Medical Sciences.
Ethic Committee of Capital Medical University Affiliated Beijing Chao-Yang Hospital.
Ethic Committee of Beijing Friendship Hospital, Capital Medical University.
Ethic Committee of Beijing Hospital of Ministry of Health.
Ethic Committee of Peking University Third Hospital.
Ethic Committee of Peking University First Hospital.
Ethic Committee of Peking University People’s Hospital.
Ethic Committee of Peking Union Medical College Hospital, Peking Union Medical College.
Ethic Committee of Xuanwu Hospital, Capital Medical University.
Ethic Committee of the General Hospital of PLA.
Ethic Committee of the First Affiliated Hospital, General Hospital of PLA.

Consent for publication

Not applicable.

Competing interests

No competing interests declared.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Cancer 1/2018 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.